TNO participates in AI-Driven Precision Pathology Company Aiosyn
Today, TNO and Aiosyn announced a strategic partnership. Aiosyn, a Dutch medical software company specializing in AI-driven pathology, recently closed a €2.4 million funding round. TNO Ventures is one of the investors, alongside OostNL, LUMO Labs, and Health Innovations. Aiosyn develops software that uses AI to accelerate histopathological diagnostics. Histopathological diagnostics is a medical examination in which diseased cells and tissues are studied microscopically to establish a diagnosis. The improved tissue analysis enables faster and more accurate detection of conditions such as breast cancer.
Over the past few years, Aiosyn has worked hard on developing three products: an AI model for breast cancer grading, a quality control model (QC), and a kidney model. Through the partnership, Aiosyn benefits from TNO’s research and lab facilities and network to accelerate the validation and implementation of the AI software.
'This funding is an important milestone for Aiosyn and underscores our mission to bring AI innovation into clinical practice. It also enables us to invest in a new generation of predictive algorithms that can transform decision-making in cancer care.'
'Our participation in Aiosyn demonstrates TNO’s role as a strategic investor in technology and innovation aimed at improving healthcare. We enjoy working with companies and startups that tackle healthcare challenges with innovative solutions. In this way, TNO contributes to high-quality, affordable, and accessible healthcare in the Netherlands.'
TNO Ventures
Earlier this year, TNO announced investments in the quantum startup Equal1 and Fortaegis. Through TNO Ventures, TNO promotes the further development and scaling of innovative technologies—a crucial step in strengthening the competitiveness and earning capacity of the Netherlands. Through licences and tech participations, companies can gain access to TNO’s technologies, expertise, and facilities, for example in AI, medical technology, and integrated photonics. Startups in which TNO participates pay in shares, reducing the cash-out for the startup. This makes TNO a strategic partner that helps drive the growth and development of innovative enterprises.
Contact us
-
Marjoleine van der Zwan
Functie:Managing Director Health & Work-
Standplaats:Leiden - Sylviusweg
-
Email:Email Marjoleine
-
Get inspired
The qubit: there and back again
TNO and Ushio, a stable partnership in advancing EUV technologies
Quantum Circles: The Foundation for Europe’s Quantum Future
Self-organising logistics
From innovation to clinical impact: TNO and Orikami accelerate the path from digital biomarker development to healthcare implementation
